As a particular finding, the data obtained this way demonstrate that broader T-cell responses with a greater diversity of CD4+ blood T-cell clones may predict longer survival of melanoma patients treated with anti-CTLA4 or PD-1 antibodies. This evidence concerns the gene PDCD1 and melanoma.